

# Ruben Mesa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/421611/publications.pdf>

Version: 2024-02-01

220  
papers

19,017  
citations

39113

52  
h-index

14012

133  
g-index

241  
all docs

241  
docs citations

241  
times ranked

15294  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study. JMIR Formative Research, 2022, 6, e33581.	0.7	4
2	Leveraging a Consumer-Based Product to Develop a Cancer-Specific Mobile Meditation App: Prototype Development Study. JMIR Formative Research, 2022, 6, e32458.	0.7	5
3	Patient and Caregiver Insights into the Disease Burden of Myelodysplastic Syndrome. Patient Related Outcome Measures, 2022, Volume 13, 31-38.	0.7	1
4	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of Clinical Oncology, 2022, 40, 1671-1680.	0.8	60
5	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances, 2022, 6, 1162-1174.	2.5	10
6	Novel treatments for myelofibrosis: beyond JAK inhibitors. International Journal of Hematology, 2022, 115, 645-658.	0.7	5
7	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	0.6	8
8	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discovery, 2022, 3, 181-193.	2.6	12
9	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	1.2	18
10	Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer, 2022, 128, 2420-2432.	2.0	24
11	Insomnia as an Unmet Need in Patients With Chronic Hematological Cancer: Protocol for a Randomized Controlled Trial Evaluating a Consumer-Based Meditation App for Treatment of Sleep Disturbance. JMIR Research Protocols, 2022, 11, e39007.	0.5	0
12	Momelotinib for the treatment of myelofibrosis with anemia. Future Oncology, 2022, 18, 2559-2571.	1.1	8
13	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT) study. British Journal of Haematology, 2022, 198, 1065-1068.	1.2	4
14	Quality of Life in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 375-390.	0.9	4
15	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere, 2021, 5, e562.	1.2	20
16	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncology, 2021, 17, 1449-1458.	1.1	31
17	Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer, 2021, 21, 691.	1.1	2
18	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	7.7	199

#	ARTICLE	IF	CITATIONS
19	TGF- $\beta$ 1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight, 2021, 6, .	2.3	31
20	MPN-164: Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S356.	0.2	7
21	Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research, 2021, 109, 106629.	0.4	3
22	The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study. Blood, 2021, 138, 3628-3628.	0.6	3
23	Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study. Blood, 2021, 138, 1507-1507.	0.6	0
24	Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leukemia and Lymphoma, 2021, , 1-15.	0.6	1
25	Treatment of Myelofibrosis Patients with the TGF- $\beta$ 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production. Blood, 2021, 138, 142-142.	0.6	10
26	Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition. Cancer Medicine, 2020, 9, 8301-8309.	1.3	12
27	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Advances, 2020, 4, 4282-4291.	2.5	77
28	Associations Between Global Mental Health and Response to an App-Based Meditation Intervention in Myeloproliferative Neoplasm Patients. Integrative Cancer Therapies, 2020, 19, 153473542092778.	0.8	21
29	Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association. Cancers, 2020, 12, 2202.	1.7	13
30	The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms. Cancer Medicine, 2020, 9, 9445-9453.	1.3	10
31	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
32	Management of challenging myelofibrosis after JAK inhibitor failure and/or progression. Blood Reviews, 2020, 42, 100716.	2.8	18
33	Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 809-817.	1.9	2
34	Management of myelofibrosis after ruxolitinib failure. Annals of Hematology, 2020, 99, 1177-1191.	0.8	62
35	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <sc>JAKARTA2</sc> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	2.0	96
36	Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 697-703.e1.	0.2	10

#	ARTICLE	IF	CITATIONS
37	Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. <i>Leukemia Research</i> , 2020, 91, 106338.	0.4	12
38	Fedratinib in myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1792-1800.	2.5	56
39	Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study. <i>Blood</i> , 2020, 136, 29-31.	0.6	9
40	Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Mometinib in JAK Inhibitor Na <sup>+</sup> ve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients. <i>Blood</i> , 2020, 136, 51-52.	0.6	12
41	Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	24
42	Rationale for and Results of a Phase I Study of the TGF- $\beta$ <sup>2</sup> 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial. <i>Blood</i> , 2020, 136, 6-8.	0.6	8
43	A Novel Educational Control Group Mobile App for Meditation Interventions: Single-Group Feasibility Trial. <i>JMIR Formative Research</i> , 2020, 4, e19364.	0.7	10
44	The Impact of COVID-19 on Cancer Screening: Challenges and Opportunities. <i>JMIR Cancer</i> , 2020, 6, e21697.	0.9	98
45	Mometinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia. <i>Blood</i> , 2020, 136, 43-44.	0.6	6
46	Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.gov Data 2010-2019. <i>Blood</i> , 2020, 136, 37-37.	0.6	2
47	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S356.	0.2	5
48	Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 121.	3.7	52
49	Oral idasanutlin in patients with polycythemia vera. <i>Blood</i> , 2019, 134, 525-533.	0.6	67
50	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019, 79, 38-44.	0.4	25
51	Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1036-1042.	0.6	1
52	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. <i>Blood</i> , 2019, 134, 557-557.	0.6	54
53	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Na <sup>+</sup> ve or were Previously Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 668-668.	0.6	16
54	Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis. <i>Blood</i> , 2019, 134, 671-671.	0.6	36

#	ARTICLE	IF	CITATIONS
55	Smartphone-Based Meditation for Myeloproliferative Neoplasm Patients: Feasibility Study to Inform Future Trials. JMIR Formative Research, 2019, 3, e12662.	0.7	66
56	Experiences of Using a Consumer-Based Mobile Meditation App to Improve Fatigue in Myeloproliferative Patients: Qualitative Study. JMIR Cancer, 2019, 5, e14292.	0.9	29
57	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	3.4	261
58	Emerging therapies for the treatment of essential thrombocythemia. Expert Opinion on Orphan Drugs, 2018, 6, 567-575.	0.5	0
59	<sup>99m</sup> Tc-Sulfur Colloid Bone Marrow Scintigraphy in Diagnosis of Diffuse Pulmonary Extramedullary Hematopoiesis Secondary to Myelofibrosis. Journal of Nuclear Medicine Technology, 2018, 46, 368-372.	0.4	11
60	Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients. Blood, 2018, 132, 4282-4282.	0.6	7
61	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). Blood, 2018, 132, 577-577.	0.6	39
62	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. Blood, 2018, 132, 686-686.	0.6	44
63	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncology, 2017, 3, 936.	3.4	90
64	Allogeneic Stem Cell Transplantation in Myelofibrosis. Biology of Blood and Marrow Transplantation, 2017, 23, 1429-1436.	2.0	29
65	Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 479-487.	0.2	21
66	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica, 2017, 102, 94-102.	1.7	80
67	Transplantation in Myelofibrosis Reaches the Molecular Age. Biology of Blood and Marrow Transplantation, 2017, 23, 1043-1044.	2.0	4
68	Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms. Haematologica, 2017, 102, e384-e388.	1.7	28
69	Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leukemia Research, 2017, 59, 26-31.	0.4	14
70	NCCN Debuts New Guidelines for Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 720-722.	2.3	3
71	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology, 2017, 4, e317-e324.	2.2	243
72	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	1.7	46

#	ARTICLE	IF	CITATIONS
73	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e225-e236.	2.2	224
74	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1193-1207.	2.3	119
75	Approach to MPN Symptom Assessment. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 381-388.	1.2	9
76	A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Leukemia Research</i> , 2017, 61, 89-95.	0.4	38
77	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017, 92, E626-E627.	2.0	3
78	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. <i>Blood</i> , 2017, 130, 1889-1897.	0.6	130
79	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. <i>Annals of Hematology</i> , 2017, 96, 1653-1665.	0.8	92
80	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , 2017, 63, 34-40.	0.4	18
81	The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. <i>Leukemia and Lymphoma</i> , 2017, 58, 1481-1487.	0.6	20
82	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). <i>British Journal of Haematology</i> , 2017, 176, 76-85.	1.2	69
83	Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. <i>Cancer</i> , 2017, 123, 449-458.	2.0	62
84	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <i>Journal of Hematology and Oncology</i> , 2017, 10, 156.	6.9	210
85	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3844-3850.	0.8	243
86	Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. <i>Journal of Experimental Pharmacology</i> , 2016, Volume 8, 11-19.	1.5	83
87	Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e324-e335.	1.8	8
88	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. <i>Cancer</i> , 2016, 122, 1888-1896.	2.0	16
89	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016, 101, 821-829.	1.7	140
90	New drugs for myelofibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 521-529.	0.5	2

#	ARTICLE	IF	CITATIONS
91	Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. <i>Blood</i> , 2016, 128, 1121-1128.	0.6	200
92	The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1101-1108.	1.1	8
93	Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 456-461.	1.2	19
94	Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocythosis myelofibrosis. <i>Haematologica</i> , 2016, 101, e405-e406.	1.7	20
95	Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. <i>European Journal of Haematology</i> , 2016, 97, 192-200.	1.1	46
96	Ruxolitinib dose management as a key to long-term treatment success. <i>International Journal of Hematology</i> , 2016, 104, 420-429.	0.7	10
97	Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. <i>Cancer</i> , 2016, 122, 477-485.	2.0	49
98	Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. <i>Haematologica</i> , 2016, 101, 660-671.	1.7	120
99	Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. <i>BMC Cancer</i> , 2016, 16, 167.	1.1	132
100	Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 151-157.	1.1	3
101	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 151-159.	0.8	56
102	Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 649-651.	0.9	1
103	Quality of life and disease understanding: impact of attending a patient-centered cancer symposium. <i>Cancer Medicine</i> , 2015, 4, 800-807.	1.3	4
104	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. <i>Haematologica</i> , 2015, 100, 479-488.	1.7	246
105	Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. <i>Mediators of Inflammation</i> , 2015, 2015, 1-9.	1.4	94
106	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. <i>Haematologica</i> , 2015, 100, 1139-1145.	1.7	203
107	Social Media and Myeloproliferative Neoplasms (MPN) – Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 413-420.	1.2	22
108	The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 114.	6.9	48



#	ARTICLE	IF	CITATIONS
109	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. <i>New England Journal of Medicine</i> , 2015, 372, 426-435.	13.9	720
110	Survival and new cancers with myeloproliferative neoplasms. <i>Lancet Haematology</i> , 2015, 2, e272-e273.	2.2	0
111	Emerging drugs for the treatment of myelofibrosis. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 663-678.	1.0	5
112	Current and future treatment options for polycythemia vera. <i>Annals of Hematology</i> , 2015, 94, 901-910.	0.8	47
113	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. <i>JAMA Oncology</i> , 2015, 1, 643.	3.4	362
114	Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1883-1887.	2.0	36
115	Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e1-e5.	0.2	22
116	Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies. <i>Blood</i> , 2015, 126, 1347-1347.	0.6	7
117	Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotinib: Correlatives from the Ym-387-II Study. <i>Blood</i> , 2015, 126, 1600-1600.	0.6	2
118	Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis. <i>Blood</i> , 2015, 126, 1618-1618.	0.6	8
119	A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET) <a href="#">Tj ETQq1 106784314rgBT /O</a>	0.6	2
120	Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience. <i>Blood</i> , 2015, 126, 2818-2818.	0.6	2
121	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2015, 126, 4073-4073.	0.6	2
122	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. <i>Blood</i> , 2015, 126, 4080-4080.	0.6	3
123	Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2015, 126, 5179-5179.	0.6	2
124	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015, 126, 56-56.	0.6	28
125	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. <i>Blood</i> , 2015, 126, 5175-5175.	0.6	0
126	Myeloproliferative Neoplasms: An in-Depth Case-Control (MOSAICC) Study. <i>Blood</i> , 2015, 126, 1621-1621.	0.6	12



#	ARTICLE	IF	CITATIONS
127	Identification and Mechanistic Characterization of CMPD1 As a Selective Sensitizer of Histone Deacetylase Inhibitors in Myeloid Malignancies. <i>Blood</i> , 2015, 126, 3689-3689.	0.6	0
128	Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 649-651.	0.9	0
129	A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis. <i>Blood</i> , 2015, 126, 2810-2810.	0.6	0
130	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. <i>Blood</i> , 2015, 126, 4370-4370.	0.6	0
131	Poor Correlation Between DIPSS and Passamonti Prognostic Risk Scores for Post Polycythemia Vera and Essential Thrombocythemia Myelofibrosis. <i>Blood</i> , 2015, 126, 1619-1619.	0.6	0
132	Living with Cancer: An Educational Intervention in Cancer Patients Can Improve Knowledge Deficit. <i>Blood</i> , 2015, 126, 3321-3321.	0.6	0
133	Therapy for myeloproliferative neoplasms: when, which agent, and how?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 277-286.	0.9	25
134	Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. <i>Leukemia and Lymphoma</i> , 2014, 55, 2368-2374.	0.6	25
135	A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 725-733.	0.5	4
136	Assessing disease burden in patients with classic MPNs. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 107-119.	0.7	7
137	Epidemiology of myeloproliferative neoplasms in the United States. <i>Leukemia and Lymphoma</i> , 2014, 55, 595-600.	0.6	195
138	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , 2014, 123, 3803-3810.	0.6	79
139	Management of thrombocythemia. <i>F1000Research</i> , 2014, 3, 227.	0.8	3
140	Letter to Our Readers. <i>American Health and Drug Benefits</i> , 2014, 7, S35.	0.5	0
141	Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2013, 54, 2226-2230.	0.6	43
142	Practical management of patients with myelofibrosis receiving ruxolitinib. <i>Expert Review of Hematology</i> , 2013, 6, 511-523.	1.0	31
143	Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1285-1292.	0.8	171
144	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013, 122, 1395-1398.	0.6	286

#	ARTICLE	IF	CITATIONS
145	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. <i>British Journal of Haematology</i> , 2013, 161, 508-516.	1.2	83
146	The evolving treatment paradigm in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 242-251.	0.6	20
147	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , 2013, 122, 394-394.	0.6	29
148	Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts $\geq 100,000/\mu\text{l}$ . <i>Blood</i> , 2013, 122, 395-395.	0.6	16
149	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. <i>Blood</i> , 2013, 122, 396-396.	0.6	21
150	Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience. <i>Blood</i> , 2013, 122, 4062-4062.	0.6	4
151	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISC). <i>Blood</i> , 2013, 122, 4088-4088.	0.6	6
152	BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses. <i>Blood</i> , 2013, 122, 603-603.	0.6	2
153	Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). <i>Blood</i> , 2013, 122, 665-665.	0.6	18
154	Pharmacological Validation Of Potentiating Targets From SAHA RNA-Interference Modifier Screens In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3832-3832.	0.6	3
155	Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. <i>Blood</i> , 2013, 122, 4090-4090.	0.6	7
156	Reduced Toxicity Conditioning With Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin Followed By Allogeneic Stem Cell Transplant For Patients With Primary and Post ET/PV Myelofibrosis: Single Center Experience At Mayo Clinic Arizona. <i>Blood</i> , 2013, 122, 2835-2835.	0.6	0
157	Improving disease burden in myelofibrosis: changing the natural history of the disease. <i>Oncology</i> , 2013, 27, 715-6.	0.4	0
158	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. <i>Journal of Clinical Oncology</i> , 2012, 30, 4098-4103.	0.8	344
159	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 799-807.	13.9	1,738
160	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. <i>Blood</i> , 2011, 118, 401-408.	0.6	280
161	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. <i>Cancer</i> , 2011, 117, 4869-4877.	2.0	50
162	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , 2011, 118, 1759-1759.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). <i>Blood</i> , 2011, 118, 2814-2814.	0.6	13
164	Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. <i>Blood</i> , 2011, 118, 282-282.	0.6	54
165	RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells., <i>Blood</i> , 2011, 118, 3513-3513.	0.6	3
166	A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),. <i>Blood</i> , 2011, 118, 3801-3801.	0.6	12
167	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. <i>Blood</i> , 2011, 118, 3839-3839.	0.6	4
168	Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML): Low Incidence of Relapse and Graft Versus Host Disease (GVHD) in Patients (pts) Transplanted without Active Leukemia Using in-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG). <i>Blood</i> , 2011, 118, 4527-4527.	0.6	0
169	Induction Therapy Followed by Allogeneic Stem Cell Transplant for MPN Blast Phase: Outcomes From Mayo Clinic in Arizona. <i>Blood</i> , 2011, 118, 1749-1749.	0.6	0
170	Pegylated Interferon Alpha “2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases. <i>Blood</i> , 2011, 118, 2818-2818.	0.6	0
171	RNAi Screening of the Human Kinome Identifies Inhibition of WEE1 Kinase As Potent and Universal Sensitizing Target to Cytarabine in Leukemias. <i>Blood</i> , 2011, 118, 229-229.	0.6	0
172	In-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG) Prevents Severe Acute and Chronic Graft Versus Host Disease (GVHD) and Allows Safe Allogeneic Stem Cell Transplantation (allo-SCT) From Mismatched, Unrelated Donors. <i>Blood</i> , 2011, 118, 1977-1977.	0.6	0
173	New Drugs for the Treatment of Myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 15-21.	1.2	8
174	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. <i>New England Journal of Medicine</i> , 2010, 363, 1117-1127.	13.9	1,046
175	Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens. <i>Blood</i> , 2010, 116, 4094-4094.	0.6	0
176	Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. <i>IDrugs: the Investigational Drugs Journal</i> , 2010, 13, 394-403.	0.7	46
177	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 471-479.	1.0	19
178	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. <i>Leukemia Research</i> , 2009, 33, 1199-1203.	0.4	203
179	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , 2009, 113, 2895-2901.	0.6	1,110
180	How I treat symptomatic splenomegaly in patients with myelofibrosis. <i>Blood</i> , 2009, 113, 5394-5400.	0.6	100

#	ARTICLE	IF	CITATIONS
181	Risk factors for leukemic transformation in patients with primary myelofibrosis. <i>Cancer</i> , 2008, 112, 2726-2732.	2.0	127
182	Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey. <i>Leukemia Research</i> , 2008, 32, 691-698.	0.4	89
183	New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. <i>Current Opinion in Hematology</i> , 2008, 15, 121-126.	1.2	10
184	Myeloproliferative disorder-associated massive splenomegaly. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 278, 281-2.	0.3	1
185	The burden of fatigue and quality of life in myeloproliferative disorders (MPDs). <i>Cancer</i> , 2007, 109, 68-76.	2.0	356
186	Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 25-33.	1.2	0
187	Choosing the Right Patients for Clinical Trials in Essential Thrombocythemia or Polycythemia Vera: Leukemic or Fibrotic Transformation Risk Assessment among 1061 Patients from a Single Institution.. <i>Blood</i> , 2007, 110, 3546-3546.	0.6	2
188	INCB018424, an Oral, Selective JAK2 Inhibitor, Shows Significant Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. <i>Blood</i> , 2007, 110, 558-558.	0.6	28
189	Erythropoietin Therapy Does Not Benefit Transfusion-Dependent Primary Myelofibrosis Patients and Treatment Response Is Infrequent with a Baseline Hemoglobin Level $\geq 10$ g/dL.. <i>Blood</i> , 2007, 110, 3555-3555.	0.6	0
190	Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies. <i>Blood</i> , 2007, 110, 1547-1547.	0.6	0
191	Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. <i>Biologics: Targets and Therapy</i> , 2007, 1, 129-38.	3.0	6
192	Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 495-517.	0.7	31
193	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2006, 108, 1158-1164.	0.6	239
194	JAK2V617F and leukemic transformation in myelofibrosis with myeloid metaplasia. <i>Leukemia Research</i> , 2006, 30, 1457-1460.	0.4	43
195	Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. <i>Cancer</i> , 2006, 107, 361-370.	2.0	165
196	Practical management of classical myeloproliferative disorder patients: a clinician's guide. <i>Future Oncology</i> , 2006, 2, 515-524.	1.1	1
197	Tipifarnib: farnesyl transferase inhibition at a crossroads. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 313-319.	1.1	48
198	TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.. <i>Blood</i> , 2006, 108, 2680-2680.	0.6	5

#	ARTICLE	IF	CITATIONS
199	MPLW515L/K and JAK2V617F Mutations: Single Colony Studies, Lineage Restriction, and Chronology of Clonal Emergence.. Blood, 2006, 108, 116-116.	0.6	6
200	Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood, 2005, 106, 318-327.	0.6	118
201	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7, 387-397.	7.7	2,695
202	Surgical and Radiotherapeutic Approaches for Myelofibrosis With Myeloid Metaplasia. Seminars in Oncology, 2005, 32, 403-413.	0.8	26
203	Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood, 2005, 105, 973-977.	0.6	351
204	Microcytosis in Myelofibrosis with Myeloid Metaplasia: Prevalence and Clinical Correlates.. Blood, 2005, 106, 4947-4947.	0.6	0
205	Pegylated interferon for the treatment of high-risk essential thrombocythemia. Haematologica, 2005, 90, 1298B.	1.7	0
206	Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia. Mayo Clinic Proceedings, 2004, 79, 883-889.	1.4	60
207	A Phase II Study of CC-5013 Treatment for Myelofibrosis with Myeloid Metaplasia: A Preliminary Report.. Blood, 2004, 104, 1505-1505.	0.6	3
208	Blood CD34 Count in Myelofibrosis with Myeloid Metaplasia: A Prospective Evaluation of Prognostic Value in 94 Patients.. Blood, 2004, 104, 662-662.	0.6	1
209	PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells.. Blood, 2004, 104, 2478-2478.	0.6	0
210	Somatic Point Mutations in RUNX1/CBFA2/AML1 Are Common in High-Risk Myelodysplastic Syndrome, but Not in Myelofibrosis with Myeloid Metaplasia.. Blood, 2004, 104, 2438-2438.	0.6	0
211	A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 2003, 101, 2534-2541.	0.6	278
212	Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Psychophysiology, 2003, 2, 264-70.	1.1	5
213	Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood, 2002, 99, 4131-4137.	0.6	58
214	Clinical and scientific advances in the philadelphia-chromosome negative chronic myeloproliferative disorders. International Journal of Hematology, 2002, 76, 193-203.	0.7	17
215	The therapy of myelofibrosis: Targeting pathogenesis. International Journal of Hematology, 2002, 76, 296-304.	0.7	4
216	Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood, 2001, 97, 3665-3667.	0.6	42

#	ARTICLE	IF	CITATIONS
217	Palliative Splenectomy in Myelofibrosis with Myeloid Metaplasia. <i>Leukemia and Lymphoma</i> , 2001, 42, 901-911.	0.6	21
218	Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1999, 106, 682-688.	1.2	43
219	Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995. , 1999, 61, 10-15.		296
220	Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995. , 1999, 61, 10.		7